The goal of this collaborative agreement is to advance the early pipeline of POLYGON Therapeutics, leveraging the full potential of its flagship molecule, PLG-101, in different cardiovascular indications to improve treatment of patients suffering from a broad panel of conditions.
Paris, France, September 8, 2022 – POLYGON Therapeutics, a French biotech company developing innovative treatments for cardiovascular diseases, announces today that a 18-month research agreement has been signed with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), acting for Inserm and Université Paris Cité. This collaboration is a logical continuation for Polygon, as the company already signed earlier in 2021 an exclusive worldwide agreement with Inserm Transfert on a portfolio of patents protecting its therapeutic development programs.
This research collaboration will involve “Immuno-metabolic mechanisms of cardiovascular diseases” Team at Paris Cardiovascular Research Center (PARCC) to generate new preclinical data for future clinical trials.
Worldwide exclusive license for POLYGON Therapeutics
POLYGON Therapeutics holds exclusive worldwide rights for patents protecting the Company’s drug candidates for relative applications in all territories. This agreement was negotiated with Inserm Transfert, extended today by a 18-month research agreement.
POLYGON Therapeutics has benefited from Inserm Transfert's support from its beginning and after its creation in 2021, through the Pre-Entrepreneurship Pathway (PPE) with a tailored assistance. POLYGON Therapeutics has successful raised 500 K€ from its inception and has also received a recognition from French market players: it has been labeled French Tech Seed and has just been awarded Laureate of the “Concours d’innovation i-Lab 2022”.
This collaboration will accelerate the research and development of the academic lab in the field of Immuno-cardiology, and will take over from the support provided by Inserm Transfert on this project and initiated nearly 7 years ago.
“Being able to collaborate with such an experienced research team is a unique opportunity for POLYGON Therapeutics” explains Mohamed ABOU ALI, CEO and co-founder of the company, adding “This collaboration will pave the way to POLYGON ambitious product platform and multi-indication strategy. The project will also explore new therapeutic target opportunities, in an attempt to build our early stage pipeline.”
“Inserm Transfert is very helpful to build a bridge between academic research and translational applications. This collaboration will help us to develop the full potential of our technology in several cardiovascular usecases and bring hope to a larger number of patients” explains Pr. Hafid AIT OUFELLA, University Professor-Hospital Practitioner, Research Unit Director @ PARCC INSERM (Paris Cardiovascular Research Center, Inserm U970 - Université Paris Cité), and CSO of POLYGON Therapeutics.
“We are very proud of this agreement and delighted to support POLYGON Therapeutics that we have been helping since the genesis of the project. This is the heart of our mission: contributing to the emergence of innovative companies based on Inserm's research built on solid foundations from the early stage. Our objective is to help create solid and long-term startups, from the concept to the licensing, able to face a worldwide competition, to fundraise and to develop future treatments for patients” states Pascale Augé, Chairman of the Executive Management Board at Inserm Transfert.
About Inserm Transfert
Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), is responsible for the value creation of innovations at Inserm and its academic partners in human health and promotes long-term technology transfers in line with international best practices. Inserm Transfert SA was founded in 2000. It manages, under a Public Service Management Contract (Consession de Service Public), the entire promotion and transfer of knowledge emerging from the Inserm research laboratories to the industrial world, from invention disclosure to industrial partnerships and startups incorporation. Inserm Transfert also offers services relating to setting up and managing national, European, and international projects, as well as supporting the technology transfer of clinical research and health data/databases. In 2009, Inserm Transfert and Inserm established an investment fund to finance proofs of concept. In 2005, Inserm Transfert Initiative, a dedicated seed money fund for life sciences, was created. Since 2017 a pathway for pre-entrepreneurship supports researchers/inventors who aspire to become involved in entrepreneurship.
More information on www.inserm-transfert.com
About POLYGON Therapeutics
POLYGON Therapeutics is a French biotech company developing innovative drugs to treat patients suffering from cardiovascular diseases. Its main drug is a first-in-class monoclonal antibody, PLG-101.
Cardiovascular Diseases (CVDs) are the number 1 cause of death globally: 18 million people died annually from CVDs over the past years, representing 31% of all global deaths. Among these deaths, 85% are due to heart attack and stroke. Despite a better management of risk factors (e.g. hypercholesterolemia and hypertension) and significant progress in CVD care, new therapeutic approaches remain untapped.
POLYGON first therapeutic solution, PLG-101, aims to target a specific immune response happening during myocardial infarction to enhance post-ischemic cardiac remodeling. It has already shown successful results on mice and pig models. and potential in other cardiovascular indications has been highlighted.
More information on www.polygon.care